Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  Genmab A/S    GMAB   DK0010272202

GENMAB A/S

(GMAB)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

BioNTech to Present Data from BNT311 and BNT131 Programs at SITC 35th Annual Meeting

10/15/2020 | 08:23am EST

Germany - BioNTech SE (Nasdaq: BNTX, 'BioNTech' or 'the Company') today announced that results from three clinical and preclinical studies have been accepted for presentation at the Society for Immunotherapy of Cancer (SITC) 35th Annual Meeting.

The data represent the first clinical results from BioNTech's ongoing collaborations with Genmab and Sanofi from both its mRNA and antibody drug class portfolios. Preliminary data from a Phase 1/2 study of DuoBody-PD-L1x4-1BB (BNT311/GEN1046) in advanced solid tumors as well as preclinical data from the program have been accepted for eposter presentations. In addition, preliminary data from the first in-human dose escalation trial of intratumoral immunotherapy BNT131 (SAR441000) in collaboration with Sanofi will be shared as e-poster presentation. The full abstracts are scheduled to be available on the SITC website on November 9, 2020.

About BioNTech

Biopharmaceutical New Technologies is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Genmab, Sanofi, Bayer Animal Health, Genentech, a member of the Roche Group, Genevant, Fosun Pharma, and Pfizer.

BioNTech's Forward-Looking Statements

This press release contains 'forward-looking statements' of BioNTech within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include, but may not be limited to, statements concerning: availabliity of clinical trial data for BioNTech's program candidates, including BNT311 (GEN1046) and BNT131 (SAR441000). Any forward-looking statements in this press release are based on BioNTech management's current expectations and beliefs of future events, and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. All information in this press release is as of the date of the release, and BioNTech undertakes no duty to update this information unless required by law.

Contact:

Jasmina Alatovic

Tel: +49 (0)6131 9084 1513

Email: Media@biontech.de

(C) 2020 Electronic News Publishing, source ENP Newswire

Stocks mentioned in the article
ChangeLast1st jan.
BIONTECH SE 1.11% 120 Delayed Quote.250.30%
GENMAB A/S -0.85% 2343 Delayed Quote.59.50%
SANOFI 0.69% 83.6 Real-time Quote.-7.35%
All news about GENMAB A/S
12/03GENMAB A/S : Announces that Janssen has Submitted a Biologics License Applicatio..
AQ
12/01GENMAB A/S : Investor Presentation - December 2020
PU
11/25NOVARTIS : Genmab Announces Enapotamab Vedotin Update
AQ
11/24GENMAB A/S : Announces Enapotamab Vedotin Update
AQ
11/24GENMAB A/S : Announces Enapotamab Vedotin Update
AQ
11/24Genmab Announces Enapotamab Vedotin Update
GL
11/24GENMAB A/S : Mereo BioPharma Group plc - Mereo BioPharma Appoints Suba Krishnan,..
AQ
11/20IMMUNOPRECISE ANTIBODIES : and Genmab Enter into a Technology Partnership Target..
AQ
11/13GENMAB A/S : 2020 Virtual Capital Markets Day – November 13, 2020
PU
11/11GENMAB A/S : Articles of association dated November 10, 2020 – English
PU
More news
Financials
Sales 2020 9 825 M 1 602 M 1 602 M
Net income 2020 4 683 M 764 M 764 M
Net cash 2020 15 035 M 2 452 M 2 452 M
P/E ratio 2020 32,5x
Yield 2020 -
Capitalization 153 B 24 990 M 24 990 M
EV / Sales 2020 14,1x
EV / Sales 2021 17,1x
Nbr of Employees 712
Free-Float 95,2%
Chart GENMAB A/S
Duration : Period :
Genmab A/S Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GENMAB A/S
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 2 203,15 DKK
Last Close Price 2 343,00 DKK
Spread / Highest target 28,0%
Spread / Average Target -5,97%
Spread / Lowest Target -90,3%
EPS Revisions
Managers
NameTitle
Jan G. J. van de Winkel President & Chief Executive Officer
Deirdre P. Connelly Chairman
Anthony Mancini Chief Operating Officer & Executive Vice President
Anthony Pagano Chief Financial Officer & Executive Vice President
Michael K. Bauer SVP, Head-Operations, Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
GENMAB A/S59.50%25 231
GILEAD SCIENCES, INC.-6.34%76 290
VERTEX PHARMACEUTICALS3.62%58 995
REGENERON PHARMACEUTICALS32.85%52 650
WUXI APPTEC CO., LTD.68.65%40 792
BIONTECH SE250.30%28 576